GlassScriptPhysician profile
Anna Khanh Le
NPI 1841382553
$4,742.80
in general payments reported to CMS, 2019-2025
32 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $408 · 2021: $966 · 2022: $1,129 · 2023: $1,012 · 2024: $445 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.66 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $751.33 | 2019-2023 | |
| Astellas Pharma US INC | $601.14 | 2022-2025 | Veozah |
| Merz North America, INC. | $400.00 | 2023 | Xeomin |
| Mayne Pharma Commercial LLC | $336.24 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $303.38 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $277.20 | 2019 | |
| Exeltis, USA INC. | $250.35 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $230.47 | 2019-2021 | |
| Daiichi Sankyo INC. | $223.96 | 2021-2025 | Injectafer |
| Pfizer INC. | $208.28 | 2020-2024 | |
| Renovia INC | $190.36 | 2021 | |
| Aspira Women'S Health INC | $144.00 | 2021-2023 | Ova1 |
| Sumitomo Pharma America, INC. | $106.21 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $88.52 | 2022 | |
| Myriad Women'S Health, INC. | $82.53 | 2023 | Myrisk |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $77.95 | 2021-2024 | Paragard T 380a |
| Lupin INC. | $67.09 | 2019-2020 | |
| Avion Pharmaceuticals | $46.99 | 2020-2022 | |
| Therapeuticsmd, INC. | $42.14 | 2020 | |
| Hologic Sales and Service, LLC | $33.03 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $33.02 | 2025 | Menopur |
| Amag Pharmaceuticals, INC. | $31.76 | 2019-2020 | |
| Evofem Biosciences, INC. | $31.60 | 2022 | |
| Dysis Medical, INC. | $29.09 | 2021-2022 | |
| Ethicon US, LLC | $24.65 | 2022 | |
| Millicent US INC | $22.52 | 2024 | Intrarosa, Femring |
| Duchesnay USA Incorporated | $21.30 | 2019 | |
| Merck Sharp & Dohme LLC | $20.74 | 2021 | |
| Axonics, INC. | $20.00 | 2023 | Axonics |
| Roche Diagnostics Corporation | $18.90 | 2019 | |
| Agile Therapeutics, INC. | $14.25 | 2021 | |
| Minerva Surgical, INC | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.